SCHEDULE 13G/A: BlackRock Amends SEC Filing, Disclosing 14.4% Stake in Glaukos Corp
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 14.4% of Glaukos Corp's common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 8,160,353 shares of Glaukos Corp common stock.
- This represents 14.4% of Glaukos Corp's total outstanding common stock.
- BlackRock holds sole voting power over 8,098,154 shares and sole dispositive power over 8,160,353 shares.
- The filing is Amendment No. 8 to Schedule 13G, indicating an update to a previously disclosed position.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Glaukos Corp.
- iShares Core S&P Small-Cap ETF, a BlackRock entity, is noted as beneficially owning more than 5% of Glaukos Corp's common stock.
Sentiment
Score: 6
Explanation: The document is a routine ownership disclosure. The presence of a significant stake by a major institutional investor like BlackRock can be viewed as a positive signal of confidence in the issuer, Glaukos Corp.
Positives
- BlackRock, Inc., a major institutional investor, holds a significant 14.4% stake in Glaukos Corp, which can be interpreted as a vote of confidence in the company's long-term prospects.
- The filing explicitly states that the securities are held in the ordinary course of business and not for the purpose of influencing control, suggesting a passive, long-term investment strategy.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates BlackRock, Inc.'s continued significant investment in Glaukos Corp, a company operating in the medical technology sector, specifically ophthalmology. Such a substantial stake from a leading asset manager like BlackRock often signals a long-term investment strategy within the healthcare industry.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock may instill confidence and potentially influence investor sentiment positively.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously effective Power of Attorney, which was revoked. |
| 2025-01-21 | Date of execution of the current Power of Attorney by BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-04-29 | Date of filing of this Schedule 13G Amendment No. 8. |
Keywords
Glaukos Corp, BlackRock, Schedule 13G, Common Stock, Institutional Ownership, Beneficial Ownership, SEC Filing, Asset Management, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.